Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026 Research and Development RWS, kayentis

Kayentis and RWS have announced a partnership aimed at improving confidence in clinical trial data for neuroscience and other complex …
News

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026 Research and Development

The Medicines and Healthcare products Regulatory Agency (MHRA) has secured new funding to expand its AI Airlock programme, aimed at …
News

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026 Research and Development Gesynta Pharma, endometriosis

Gesynta Pharma has dosed the first patient in its phase 2 clinical proof-of-concept trial of vipoglanstat. The trial, NOVA, is …
News

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026 Research and Development

Kainova Therapeutics has announced that the first patient in the European expansion of its DOMISOL phase I/II clinical trial evaluating …
News
drug-trials

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026 Research and Development

Eisai is to begin enrolling participants in its phase 2 study, Study 202, in patients with narcolepsy. The company registered …
News

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026 Research and Development AI, NVIDIA, Roche

Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance graphics processing units (GPUs) across …
News

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026 Research and Development EndoCyclic Therapeutics, FDA, endometriosis

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved by the US FDA. With …
News

Outrun Therapeutics announces its lead programme for HPV positive cancer

March 23, 2026 Research and Development HPV, Oncology, Outrun Therapeutics

Outrun Therapeutics has selected an E6AP inhibitor strategy as its lead programme for treating HPV positive head and neck cancer. …
News

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026 Research and Development NHS, University of Huddersfield, West Yorkshire

Dr Zubir Ahmed MP, the Under-Secretary of State for Health Innovation and Safety, has visited the recently opened Emily Siddon …
News

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026 Research and Development DiaMedica, Health Canada, preeclampsia

DiaMedica Therapeutics has received a No Objection Letter (NOL) from Health Canada, giving the company regulatory clearance to start its …
News

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026 Research and Development Abselion, The Engine, US

Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. The company aims to strengthen …
News

Antiverse receive investment from IIC and Development Bank of Wales

March 9, 2026 Research and Development Antiverse, Wales, funding

As part of its $9.3m Series A funding round, Antiverse has received a joint equity investment by Innovation Investment Capital …
News

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

March 6, 2026 Research and Development Curie.Bio, Secarna Pharmaceuticals, partnership

Secarna Pharmaceuticals has announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio. The collaboration, first announced …
News

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026 Research and Development Siemens Healthineers

Siemens Healthineers has opened a new Centre of Excellence for Immunoassay Instrument Research & Development in Swords, Ireland. Over 10m …
News

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026 Research and Development Eylea HD, Opthalmology, Regeneron

Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease. The data was presented as part of …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026